Phase in Biological Technology

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive res...

Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure

SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatme...

OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.

FT. LAUDERDALE, Fla., Aug. 4 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that the company has acquired the EDC assets of UK based, clinical software provider, Lo...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosi...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance o...

Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide eClinical Solutions for Phase IV Studies

FT. LAUDERDALE, Fla., July 30 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that a growing US Clinical Research Organization (CRO) has selected OmniComm to pr...

Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications

SAN DIEGO, Calif., July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) and its subsidiary Tissue Repair Company (TRC) today provided an update on the completion of their MATRIX Phase 2b clinical study and announced plans to provide detailed safety and efficacy...

PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial

SAN DIEGO and LOS ANGELES, July 27 /PRNewswire/ -- PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, and the University of Southern California (USC) announced today that they have signed an agreement whereby PacificGMP will prov...

PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2

SOUTH PLAINFIELD, N.J., July 27 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant brain tumors....

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy

Efficacy and Safety Study in Patients with Moderate to Severe Post-Operative Pain SYDNEY, Australia and BEDMINSTER, N.J., July 23 /PRNewswire-FirstCall/ -- QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation of a Phase 2 comparative proof-...

Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV

PRINCETON, N.J. and SAN DIEGO, July 22 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and result...

Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi-Year Marketing Agreement with Phase Forward

PRINCETON, N.J., July 15 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD ) today announced it has signed an agreement to sell its Interactive Voice & Web Response Services (IVRS/IWRS) business to Phase Forward (Nasdaq: PFWD ). In addition, Covance and Phase Forward have agree...

EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer's Disease

VIENNA, July 15 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the successful completion of a phase Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good...

Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study

GOTHENBORG, Sweden, July 14 /PRNewswire/ -- PharmaSurgics AB. successfully completes Phase I clinical study showing their novel candidate drug PXL01 is safe and well tolerated. Initially developed to prevent post-surgical adhesion formation following hand surgery the product combines the pharm...

MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus

ROCKVILLE, Md. , July 13 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the treatment of individuals with suspected central nervous system infection due to West Nile Viru...

Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032 , the...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP ) today announced results from the Phas...

Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus

ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoSta...

Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma

Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 c...

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy

- Insmed to Evaluate Potential Initiation of Phase II Trial for IPLEX(TM) in MMD Patients with Severe Insulin Resistance - RICHMOND, Va. , June 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM ), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II ...

Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials

Release Highlights - Melogliptin continues to demonstrate potential to be the best-in-class in achieving glycemic control with low incidence of hypoglycemia and neutral effect on body weight - Global Phase III trials likely to start by end 2009 - IND approved by USFD...

OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

BOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) via the special protocol assessment process (SPA) on an amendment to the design ...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

MISSISSAUGA, ON, June 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that its li...

Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer

SEATTLE, June 22 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY) (the "Company") today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally ad...

METTLER TOLEDO Introduces an Affordable Reaction Block for Solid Phase Peptide Synthesis (SPPS)

METTLER TOLEDO offers an affordable reaction block for solid phase peptide synthesis and purification of peptide libraries: MiniBlock. For a limited time, you can register to win a MiniBlock® for Solid Phase Peptide Synthesis (SPPS). Columbia, MD (PRWEB) June 21, 2...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

- Trial conducted by Novartis evaluating safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., June 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announce...

Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections

ASHBURN, Va., June 18 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced positive provisional findings from its three phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

WARRENDALE, Pa., June 16 /PRNewswire/ -- Three Rivers Pharmaceuticals announced today positive results of the U.S.-based, randomized Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University , an...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic...

Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease

SAN FRANCISCO, June 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer's d...

New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease

COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE ) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide cov...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today disclosed preliminary results for the Company's European multi-center Phase 2 trial in non-small cell lung cancer (NSC...

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on thri...

Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

DUROS(R) continuous delivery of exenatide produces impressive reductions in fasting plasma glucose, HbA1c and body weight during 28-day treatment NEW ORLEANS, June 8 /PRNewswire/ -- Intarcia Therapeutics, Inc. today presented results from the first clinical study of ITCA 650 (DUROS(R) continu...

Diamyd(R) Phase III Study Approved for Younger Patients in the US

STOCKHOLM, June 8 /PRNewswire-FirstCall/ -- Diamyd Medical reported today that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company's Phase III study with the diabetes vaccine Diamyd(R). ...

D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients

REHOVOT, Israel, June 8 /PRNewswire/ -- D-Pharm announced today that its Investigational New Drug (IND) application for a pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients has been approved by the US Food and Drug Administration (FDA). D-Pharm plans to initiate the t...

Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator, Mark A...

Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis

NOVATO, Calif., June 1 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel - - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort - ORLANDO, Fla. and ...

Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors

- Results Presented at American Society of Clinical Oncology (ASCO) Meeting Show Fleximer(R) Conjugated Drug Is Well Tolerated with Favorable Pharmacokinetics and Prolonged Stable Disease in Refractory Tumors - CAMBRIDGE, Mass., June 1 /PRNewswire/ -- Mersana Therapeutics presented preliminar...